Ocular manifestations of rheumatologic disorders.
In the past year, advances have been made in our understanding of the genetics of Behçet disease. Indocyanine green angiography has allowed us to look at the pathologic changes seen in Behçet disease and sarcoidosis in more detail. New steroid-sparing treatment strategies for the control of ocular inflammatory disease are becoming better understood and better used, and their applications in sarcoidosis and juvenile chronic arthritis are reviewed here. The role of antiphospholipid antibodies in ocular disease has received attention, particularly in the context of systemic lupus erythematosus. Outcomes in HLA-B27-positive patients with uveitis and in ocular disease associated with the systemic vasculitides are discussed here, and scalp necrosis in giant-cell arteritis is reviewed.
Poole
T R
TR
Medical Eye Unit, St Thomas' Hospital, London, UK.
Graham
E M
EM
D003937:Diagnosis, Differential; D005128:Eye Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D011379:Prognosis; D012216:Rheumatic Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy
D005938:Glucocorticoids